Oliver Lagore Vanvalin Investment Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Oliver Lagore Vanvalin Investment Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-12	Closed	-$1.34K	–	708
2024 Q3	$1.34K	Hold	12	–	–	﹤0.01%	604
2024 Q2	$1.28K	Hold	12	–	–	﹤0.01%	636
2024 Q1	$1.45K	Hold	12	–	–	﹤0.01%	640
2023 Q4	$1.48K	Hold	12	–	–	﹤0.01%	653
2023 Q3	$1.55K	Hold	12	–	–	﹤0.01%	719
2023 Q2	$1.49K	Hold	12	–	–	﹤0.01%	672
2023 Q1	$1.76K	Hold	12	–	–	﹤0.01%	596
2022 Q4	$1.91K	Sell	12 -1	-8%	-$147	﹤0.01%	560
2022 Q3	$2K	Hold	13	–	–	﹤0.01%	530
2022 Q2	$2K	Hold	13	–	–	﹤0.01%	500
2022 Q1	$2K	Buy	+13	New	+$1.89K	﹤0.01%	506

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Oliver Lagore Vanvalin Investment Group's JAZZ Position: Q4 2024 in Review

Oliver Lagore Vanvalin Investment Group sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2024, closing a stake of 12 shares — an estimated $1.34K sold.

Oliver Lagore Vanvalin Investment Group first reported a position in JAZZ in Q1 2022 and held it in 11 quarters. The position peaked at $2K in Q3 2022. 508 funds tracked by Wall St. Rank hold JAZZ as of Q4 2024.

Oliver Lagore Vanvalin Investment Group reported no remaining Jazz Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Oliver Lagore Vanvalin Investment Group sold 12 Jazz Pharmaceuticals shares in Q4 2024, an estimated $1.34K.
Oliver Lagore Vanvalin Investment Group first reported a position in Jazz Pharmaceuticals in Q1 2022 and held it in 11 quarters.
Oliver Lagore Vanvalin Investment Group's Jazz Pharmaceuticals position peaked at $2K in Q3 2022.
508 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2024.

Based on Oliver Lagore Vanvalin Investment Group's 13F filing for Q4 2024, filed 1 Apr 2025.